pharmacology_9th_edition_mccuistion_test_bank.p

PHARMACOLOGY 9T`
73

, Test73Bank73-73Pharmacology:73A73Patient-
Centered73Nursing73Process73Approach73(9th73Edition,732017)
PHARMACOLOGY739TH73EDITION73MCCUISTION73TEST73BANK


Table73of73Contents
Table73of73Contents Chapter7328:73Peptides,7
3Antimalarial,73and

Chapter7301:73Drug73Development73and Anthelmintic
73Ethical73Considerations Chapter7329:73HIV-73and73AIDS-
Chapter7302:73Pharmacokinetics,73 Related73Drugs
Pharmacodynamics,73and73Pharm Chapter7330:73Transplant73Drug
acogenetics s73Chapter7331:73Vaccines73Cha
Chapter7303:73Cultural73Considerations7 pter7332:73Anticancer73Drugs
3Chapter7304:73Complementary73and73A Chapter7333:73Targeted73Therapies73to73Tre
lternative73Therapies at73Cancer
Chapter7305:73Pediatric73Considerations7 Chapter7334:73Biologic73Respons
3Chapter7306:73Geriatric73Considerations e73Modifiers
73Chapter7307:73Drugs73in73Substance73U Chapter7335:73Upper73Respirator
se73Disorder y73Disorders
Chapter7308:73The73Nursing73Process73an Chapter7336:73Lower73Respirator
d73Patient-Centered73Care y73Disorders
Chapter7309:73Safety73and73Quality7 Chapter7337:73Cardiac73Glycosides,73
3Chapter7310:73Drug73Administratio Antianginals,73and73Antidysrhythmics
n73Chapter7311:73Drug73Calculation 73Chapter7338:73Diuretics
s73Chapter7312:73Fluid73Volume73an Chapter7339:73Antihypertensive
d73Electrolytes Chapter7340:73Anticoagulants,73Antipla
Chapter7313:73Vitamin73and73Miner telets,73and73Thrombolytics73Chapter73
al73Replacement 41:73Antihyperlipidemics73and73Periph
Chapter7314:73Nutritional73Support73Cha eral73Vasodilators
pter7315:73Adrenergic73Agonists73and73A Chapter7342:73Gastrointestinal73Tract
ntagonists 73Disorders
Chapter7316:73Cholinergic73Agonists73and Chapter7343:73Antiulcer73Drugs73Chapt
73Antagonists er7344:73Eye73and73Ear73Disorders73Ch
Chapter7317:73Stimulants apter7345:73Dermatologic73Disorders73
Chapter7318:73Depressants73Chap Chapter7346:73Pituitary,73Thyroid,73Par
ter7319:73Antiseizure73Drugs athyroid,73and73Adrenal73Disorders73C
Chapter7320:73Drugs73for73Parkinsonism73an hapter7347:73Antidiabetics
d73Alzheimer's73Disease Chapter7348:73Urinary73Disorders73Cha
Chapter7321:73Drugs73for73Neuromuscular pter7349:73Pregnancy73and73Preterm73L
73Disorders73and73Muscle73Spasms73Chap abor
ter7322:73Antipsychotics73and73Anxiolytic Chapter7350:73Labor,73Delivery,73a
s nd73Postpartum
Chapter7323:73Antidepressants73and73Mood Chapter7351:73Neonatal73and73Newbor
73Stabilizers n73Chapter7352:73Women's73Reproduct
Chapter7324:73Antiinflammatories ive73Health
Chapter7325:73Analgesics Chapter7353:73Men's73Reproductive73Healt
Chapter7326:73Antibacterials h73Chapter7354:73Sexually73Transmitted73I
Chapter7327:73Antituberculars,73Antifungals,7 nfections
3and73Antivirals Chapter7355:73Adult73and73Pediatr

, Test73Bank73-73Pharmacology:73A73Patient-
Centered73Nursing73Process73Approach73(9th73Edition,732017)
PHARMACOLOGY739TH73EDITION73MCCUISTION73TEST73BANK
ic73Emergency73Drugs

, Test73Bank73-73Pharmacology:73A73Patient-
Centered73Nursing73Process73Approach73(9th73Edition,732017)
PHARMACOLOGY739TH73EDITION73MCCUISTION73TEST73BANK



Chapter7301:73Drug73Development73and73Ethical73Considerations
MULTIPLE73CHOICE
1. The73nurse73is73preparing73to73administer73a73schedule73II73injectable73drug73and73is73dr
awing73up73half73of73the73contents73of73a73Single-
use73vial.73Which73nursing73action73is73correct?
a. Ask73another73nurse73to73observe73and73cosign73wasting73the73remaining73drug73from73the73
vial.
b. Keep73the73remaining73amount73in73the73patient’s73drawer73to73give73at73the73next73dose.
c. Record73the73amount73unused73in73the73patient’s73medication73record.
d. Dispose73of73the73vial73with73the73remaining73drug73into73a73locked73
collection73box.73ANS:73A
Schedule73II73drugs73are73controlled73substances,73and73all73must73be73accounted73for.73
When73wasting73a73portion73of73a73drug,73another73nurse73should73observe73and73cosign73
that73a73drug73was73wasted.
DIF:73COGNITIVE73LEVEL:73Applying73(Applicat
ion)73TOP:73NURSING73PROCESS:73Nursing73I
ntervention
MSC:73NCLEX:73Physiological73Integrity:73Pharmacological73and73Parenteral73Therapies

2. A73patient73is73prescribed73a73medication73and73asks73the73nurse73if73the73drug73is73avai
lable73in73a73generic73form.73The73nurse73understands73that73a73generic73medication73will73
have73a73name73that
a. is73a73registered73trademark.
b. is73always73capitalized.
c. describes73the73drugs73chemical73structure.
d. is73non-
proprietary.73ANS:73
D
The73generic73name73is73the73official,73non-
proprietary73name73for73a73drug.73The73brand73name73is73the73trademark73name73and73is73alw
ays73capitalized.73The73chemical73name73describes73the73chemical73structure73of73the73drug.
DIF:73COGNITIVE73LEVEL:73Understanding73(Comprehen
sion)73TOP:73NURSING73PROCESS:73N/A
MSC:73NCLEX:73Physiological73Integrity:73Pharmacological73and73Parenteral73Therapies

3. A73patient73receives73a73prescription73on73which73the73provider73has73noted73that73a73ge
neric73medication73may73be73given.The73patient73asks73the73nurse73what73this73means.73W
hat73will73the73nurse73tell73the73patient73about73generic73drugs?
a. They73contain73the73same73inert73ingredients73as73brand-name73drugs.
b. They73have73chemical73structures73that73are73identical73to73proprietary73drugs.
c. They73tend73to73be73less73expensive73than73brand-name73drugs.
d. They73undergo73extensive73testing73before73they73are73
marketed.73ANS:73C
Generic73drugs73are73approved73by73the73FDA73if73they73are73proved73to73be73bioequivalent73t
o73the73brand-
73name73drug.73They73tend73to73be73less73expensive73because73manufacturers73of73these73dr
ugs73do73not73have73to73do73the73extensive73testing73required73of73brand-